Featured article: NOACs replace VKA as preferred oral anticoagulant among new patients: a drug utilization study in 560 pharmacies in The Netherlands
In 2012, around 400.000 patients in the Netherlands were treated with Vitamin K Antagonists (VKA) for thromboembolic diseases. Since 2011, non-VKA oral anticoagulants (NOACs) are available. NOACs do not require frequent INR monitoring which benefits patients, but also imposes a risk of reduced therapy adherence. The objective of this study is to describe uptake and patient adherence of NOACs in The Netherlands until October 2016.
World Thrombosis Day: preventing thrombosis and promoting high quality of life
October 13th is World Thrombosis Day, a global movement that aims to focus attention on thrombosis, an often overlooked and misunderstood condition. To mark the occasion we invited Tetsumei Urano, an Associate Editor for Thrombosis Journal to tells us about the conditions that the day focuses on.
Aims and scope
Thrombosis Journal is an open-access journal that publishes original articles on aspects of clinical and basic research, new methodology, case reports and reviews in the areas of thrombosis.
Topics of particular interest include the diagnosis of arterial and venous thrombosis, new antithrombotic treatments, new developments in the understanding, diagnosis and treatments of atherosclerotic vessel disease, relations between haemostasis and vascular disease, hypertension, diabetes, immunology and obesity.
Latest article series and supplements
The 9th Congress of the Asian-Pacific Society on Thrombosis and Hemostasis was held from 6-9 October 2016 in Taipei, Taiwan.
As the official journal of the APSTH, Thrombosis Journal has published a supplement of state of the art review and research articles in conjunction with the congress.
Inflammation and its role in thrombosis
In recent years it has become increasingly clear that the immune system and coagulation pathways interact and influence one another. Inflammation-induced thrombosis is considered a feature of several autoimmune diseases and thus such findings have important consequences for the treatment and management of such diseases.
Editors' quotes
"Open access is a critical element in dissemination of knowledge and research data throughout the world. In the field of thrombosis and haemostasis many developments are relevant, not only for the developed world, but also for those in underdeveloped nations where access to journals may be limited. The strength of Thrombosis Journal is that is can be accessed by everyone, everywhere. I strongly encourage scientists to submit their valuable data (clinical and basic research) to Thrombosis Journal, where we provide a platform for the full range of thrombosis and haemostasis related topics (also including case reports and special issue contributions)."
Hugo ten Cate, Editor-in-Chief, Thrombosis Journal
"Treatment and prophylaxis of thrombotic and bleeding disorders is of great importance to the worldwide population, and there is a great need to facilitate the research activities related to this field. The aim of Thrombosis Journal is to provide a platform on which these important studies are visible to all members of the scientific community and public."
Yukio Ozaki, Editor-in-Chief, Thrombosis Journal
Advertisement
Official journal of
-
Thrombosis Journal is the official journal of the Asian-Pacific Society on Thrombosis and Hemostasis.
Members of APSTH are entitled to a 15% discount on the article processing charge.
Follow
2017 Journal Metrics
-
Speed
42 days from submission to first decision
99 days from submission to acceptance
14 days from acceptance to publicationCitation Impact
1.077 - Source Normalized Impact per Paper (SNIP)
1.009 - SCImago Journal Rank (SJR)
2.9 - CitescoreUsage
343,125 downloads
147 Altmetric Mentions
Advertisement
